Browse by author
Lookup NU author(s): Dr Emma Bell,
Dr Lindi Chen,
Professor John Lunec,
Professor Deborah Tweddle
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The MYCN oncogene encodes a transcription factor which is amplified in up to 40% of high risk neuroblastomas. MYCN amplification is a well-established poor prognostic marker in neuroblastoma, however the role of MYCN expression and the mechanisms by which it acts to promote an aggressive phenotype remain largely unknown. This review discusses the current evidence identifying the direct and indirect downstream transcriptional targets of MYCN from recent studies, with particular reference to how MYCN affects the cell cycle, DNA damage response, differentiation and apoptosis in neuroblastoma. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
Author(s): Bell E, Chen LD, Liu T, Marshall GM, Lunec J, Tweddle DA
Publication type: Review
Publication status: Published
Journal: Cancer Letters
Print publication date: 01/07/2010
ISSN (print): 0304-3835
ISSN (electronic): 1872-7980
Publisher: ELSEVIER IRELAND LTD